Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Insulin resistance and hyperglycemia predispose individuals with type 2 diabetes mellitus (T2DM) to endothelial dysfunction and a greater risk of cardiovascular diseases (CVD). Increased CVD risk in individuals with T2DM persists despite optimal pharmacological therapy, highlighting the need to identify complementary lifestyle interventions that improve cardiometabolic functions in this population. Evidence from animal models suggests that heat exposure improves metabolic functions. Notably, weekly heat exposure for 16 weeks blunts hyperinsulinemia and hyperglycemia induced by a high fat diet in mice. In parallel, studies in humans have shown that heat exposure improves vascular endothelial function. Based on such findings, it has been suggested that heat therapy may represent an effective lifestyle intervention to improve cardiometabolic functions. However, only 1 study has examined the impact of a heat therapy intervention on individuals with T2DM, demonstrating that 6 weeks of heat exposure reduces fasting plasma glucose and hemoglobin A1C. No study has considered potential vascular benefits of heat therapy in individuals with T2DM.
This project will investigate cardiometabolic responses to repeated heat exposure in men and women with T2DM. We will test the hypothesis that 12 weeks of heat therapy improves postprandial fatty acid handling, insulin sensitivity and endothelial function in individuals with T2DM.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Thermoneutral | Sham Comparator | Participants will immerse their feet in a foot bath with water maintained at 36°C |
|
| Heat | Experimental | Participants will immerse their feet in a foot bath with water maintained at 42°C |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Thermoneutral water | Other | Participants will immerse their feet in a foot bath that contains thermoneutral water |
|
| Measure | Description | Time Frame |
|---|---|---|
| Hemoglobin A1C (HbA1C) | Change from baseline to 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Insulin resistance (HOMA-IR) | Change from baseline to 12 weeks | |
| Postprandial metabolism following meal | Quantified over a 6-hour period following the ingestion of a standardized liquid meal | Change from baseline to 12 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Daniel Gagnon, PhD | Contact | 514-374-1480 | 4205 | daniel.gagnon.3@umontreal.ca |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre ÉPIC, Montreal Heart Institute | Recruiting | Montreal | Quebec | H1T1N6 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Hot water | Other | Participants will immerse their feet in a foot bath that contains hot water |
|
| Peripheral endothelial function | Brachial artery flow-mediated dilation | Change from baseline to 12 weeks |
| Post-occlusion reactive hyperemia | Reactive hyperemia following 5 minutes of forearm ischemia | Change from baseline to 12 weeks |
| Ischemic handgrip exercise | Reactive hyperemia following ischemic handgrip exercise | Change from baseline to 12 weeks |
| Arterial stiffness | Carotid-femoral pulse wave velocity | Change from baseline to 12 weeks |
| Blood pressure | 24-hour ambulatory blood pressure monitoring | Change from baseline to 12 weeks |
| D004700 | Endocrine System Diseases |